Bo Cumbo'un ücretlendirmesi Solid Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$102m
Jun 30 2024	n/a	n/a	-US$91m
Mar 31 2024	n/a	n/a	-US$90m
Dec 31 2023	US$919k	US$585k	-US$96m
Sep 30 2023	n/a	n/a	-US$91m
Jun 30 2023	n/a	n/a	-US$90m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$4m	US$46k	-US$86m

Tazminat ve Piyasa: Bo 'nin toplam tazminatı ($USD 918.55K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.41M ).

Tazminat ve Kazançlar: Bo 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bo Cumbo (53 yo)

2yrs

Görev süresi

US$918,550

Tazminat

Mr. Alexander G. Cumbo, also known as Bo, serves as President, Chief Executive Officer and Director at Solid Biosciences Inc. since December 02, 2022. He serves as Independent Director of Verve Therapeutic...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ian Smith	Executive Chair	4.7yrs	US$828.65k	0.27% $ 456.4k
Alexander Cumbo	President	2yrs	US$918.55k	0.096% $ 160.1k
Ilan Ganot	Co-founder	11.9yrs	US$902.09k	0.31% $ 514.6k
Kevin Tan	CFO & Treasurer	1.9yrs	US$1.36m	0.023% $ 38.7k
David Howton	COO, General Counsel & Secretary	2yrs	US$648.88k	0.039% $ 65.2k
Annie Ganot	Co-Founder & Head of Patient Advocacy	no data	Veri yok	Veri yok
Paul Herzich	Chief Technology Officer	2yrs	Veri yok	0.030% $ 50.7k
Allison Bogosian	Senior Vice President of Human Resources	2.9yrs	Veri yok	Veri yok
Jessie Hanrahan	Chief Regulatory Officer	2yrs	Veri yok	0.036% $ 59.2k
Shuli Kulak	Head of Corporate Strategy & Business Development	1.3yrs	Veri yok	Veri yok
Gabriel Brooks	Chief Medical Officer	1.2yrs	Veri yok	0.027% $ 45.7k

2.0yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: SLDB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ian Smith	Executive Chair	4.7yrs	US$828.65k	0.27% $ 456.4k
Alexander Cumbo	President	2yrs	US$918.55k	0.096% $ 160.1k
Ilan Ganot	Co-founder	11.9yrs	US$902.09k	0.31% $ 514.6k
Jeffrey Bluestone	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Geoffrey Slaff	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Laurence Turka	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Chamberlain	Chairman of Scientific Advisory Board	6.9yrs	Veri yok	Veri yok
Adam Stone	Lead Independent Director	9.1yrs	US$109.72k	0% $ 0
Lynne Sullivan	Independent Director	9.1yrs	US$113.22k	0% $ 0
Carrie Miceli	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ronald Cohn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Dongsheng Duan	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

8.0yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SLDB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 02:33
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Solid Biosciences Inc. 19 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Huidong Wang	Barclays
Timothy Chiang	BTIG
Charles Duncan	Cantor Fitzgerald & Co.

Solid Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

President notifies of intention to sell stock

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Solid Biosciences Inc. Announces Executive Changes

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Recent updates

President notifies of intention to sell stock

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Price target decreased by 9.0% to US$18.00

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Price target increased by 13% to US$19.78

Consensus revenue estimates increase by 123%

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Consensus forecasts updated

Price target decreased to US$3.00

Solid Biosciences Inc. Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results

Consensus forecasts updated

Solid Biosciences Inc. (NasdaqGS:SLDB) entered into a definitive agreement to acquire AavantiBio, Inc.

Solid Biosciences to acquire gene therapy company AavantiBio

Bain Capital Engages in Discussions with Solid Biosciences

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Solid Biosciences Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq for Minimum Bid Price Requirement

Price target decreased to US$5.60

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Price target decreased to US$8.67

Solid Biosciences Inc. to Report Q1, 2022 Results on Apr 27, 2022

Price target decreased to US$8.67

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Price target decreased to US$7.40

Price target decreased to US$7.42

Price target decreased to US$8.50

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Solid Biosciences Inc. Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Solid Biosciences Inc. to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Consensus forecasts updated

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell 2500 Growth Index

Co-Founder & Independent Director Matthew Arnold has left the company

Solid Biosciences Inc Announces Two Additional Patients Dosed in the IGNITE DMD Clinical Trial

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing Ignite Dmd Clinical Trial and Resumption of Patient Dosing in the 2E14 Vg/Kg Cohort

Solid Biosciences Inc. Announces Management Changes

New 90-day high: US$9.74

CFO & Treasurer has left the company

Co-founder exercised options and sold US$66k worth of stock

Soild Bio sinks 13% after Sarepta data misses goal

New 90-day high: US$7.79

New 90-day high: US$5.60